Cyclosporin microemulsion. A guide to usage and monitoring

BioDrugs

Volumn 7, Issue 3, 1997, Pages 175-197

  Holt, David W ^a   Johnston, Atholl ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A;

AREA UNDER THE CURVE; AUTOIMMUNITY; BIOEQUIVALENCE; CLINICAL TRIAL; CYSTIC FIBROSIS; DISEASE MANAGEMENT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG METABOLISM; DRUG MONITORING; DRUG THERAPY; GASTROINTESTINAL TOXICITY; GINGIVA HYPERPLASIA; GRAFT REJECTION; HEADACHE; HUMAN; HYPERTRICHOSIS; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MICROEMULSION; NAUSEA; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; PARESTHESIA; PRIORITY JOURNAL; REVIEW; VARIANCE;

EID: 0030743633     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199707030-00002     Document Type: Review

References (106)

1. Borel JF, Kis ZL, Beveridge T. The history of the discovery and development of cyclosporine (Sandimmune). In: Merluzzi VJ, Adams J, editors. The search for anti-inflammatory drugs. Boston: Birkhauser, 1995: 27-63
2. Stahelin HF. The history of cyclosporin A (Sandimmune®) revisited: another point of view [abstract]. Experientia 1996; 52: 5-13
3. Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporin [review]. Clin Pharmacokinet 1986; 11: 107-32
4. Lindholm A. Factors influencing the pharmacokinetics of cyclosporine in man [review]. Ther Drug Monit 1991; 13: 465-77
5. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205-18
6. Yatscoff RW, Shaw LM. Therapeutic monitoring of cyclosporine, FK-506, and rapamycin [editorial]. Ther Drug Monit 1992; 14: 267-8
7. Sketris I, Yatscoff R, Keown P, et al. Optimizing the use of cyclosporine in renal transplantation [review]. Clin Biochem 1995; 28: 195-211
8. Holt DW, Johnston A. Cyclosporin A: analytical methodology and factors affecting therapeutic drug monitoring. Ther Drug Monit 1995; 17: 625-30
9. Kahan BD, Shaw LM, Holt D, et al. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine [review]. Clin Chem 1990; 36: 1510-6
10. Shaw LM, Yatscoff RW, Bowers LD, et al. Canadian Consensus Meeting on cyclosporine monitoring: report of the consensus panel [review]. Clin Chem 1990; 36: 1841-6
11. Holt DW, Johnston A, Roberts NB, et al. Methodological and clinical aspects of cyclosporin monitoring: report of the Association of Clinical Biochemists task force [review]. Ann Clin Biochem 1994; 31: 420-46
12. Morris RG, Tett SE, Ray JE. Cyclosporin A monitoring in Australia: consensus recommendations. Ther Drug Monit 1994; 16: 570-6
13. Oellerich M, Armstrong VW, Kahan B, et al. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit 1995; 17: 642-54
14. Kahan BD, Welsh M, Rutzky LP. Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring [review]. Ther Drug Monit 1995; 17: 621-4
15. Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995; 59: 505-11
16. Vonderscher J, Meinzer A. Rationale for the development of Sandimmune Neoral. Transplant Proc 1994; 26: 2925-7
17. Holt DW, Mueller EA, Kovarik JM, et al. The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine. Transplant Proc 1994; 26: 2935-9
18. Holt DW, Mueller EA, Kovarik JM, et al. Sandimmun Neoral pharmacokinetics: impact of the new oral formulation [review]. Transplant Proc 1995; 27: 1434-7
19. Noble S, Markham A. Cyclosporin: a review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Drugs 1995; 50: 924-41
20. Kovarik JM, Mueller EA, Niese D. Clinical development of a microemulsion formulation of cyclosporine. Ther Drug Monit 1996; 18: 429-34
21. Drewe J, Beglinger C, Kissel T. The absorption site of cyclosporin in the human gastrointestinal tract. Br J Clin Pharmacol 1992; 33: 39-43
22. Mehta MU, Venkataramanan R, Burckart GJ, et al. Effect of bile on cyclosporin absorption in liver transplant patients. Br J Clin Pharmacol 1988; 25: 579-84
23. Howrie DL, Ptachcinski RJ, Griffith BP, et al. Anaphylactoid reactions associated with parenteral cyclosporine use: possible role of Cremophor EL. Drug Intell Clin Pharm 1985; 19: 425-7
24. Trull AK, Tan KK, Uttridge J, et al. Cyclosporin absorption from microemulsion formulation in liver transplant recipient [letter]. Lancet 1993; 341: 433
25. Ptachcinski RJ, Venkataramanan R, Rosenthal JT, et al. The effect of food on cyclosporine absorption. Transplantation 1985; 40: 174-6
26. Burckart GJ, Starzl TE, Brittion K, et al. Cyclosporine monitoring and pharmacokinetics in paediatric liver transplant patients. Transplant Proc 1995; 17: 1172-5
27. Atkinson K, Biggs JC, Brition K, et al. Oral absorption of cyclosporin A for recipients of allogenic marrow transplants: implications of clinical gut dysfunction. Br J Haematol 1984; 56: 223-31
28. Tewari A, Ward RG, Sells RA, et al. Reduced bioavailability of cyclosporin A capsules in a renal transplant patient with partial gastrectomy and ileal resection. Ann Clin Biochem 1993; 30: 587-9
29. Whitington PF, Emond JC, Whitington SH, et al. Small-bowel length and the dose of cyclosporine in children after liver transplantation. N Engl J Med 1990; 322: 733-8
30. Kovarik JM, Mueller EA, van Bree JB, et al. Reduced inter-and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994; 83: 444-6
31. Lindholm A, Welsh M, Alton C, et al. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin Pharmacol Ther 1992; 52: 359-71
32. Schroeder TJ, Hariharan S, First MR. Relationship between cyclosporine bioavailability and clinical outcome in renal transplant recipients. Transplant Proc 1994; 26: 2787-90
33. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43: 630-5
34. Combalbert J, Fabre I, Fabre G, et al. Metabolism of cyclosporin A. IV: purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989; 17: 197-207
35. Kolars JC, Awni WM, Merion RM, et al. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338: 1488-90
36. Lang CC, Brown RM, Kinirons MT, et al. Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism. Clin Pharmacol Ther 1996; 59: 41-6
37. Webber IR, Peters WH, Back DJ. Cyclosporin metabolism by human gastrointestinal mucosal microsomes. Br J Clin Pharmacol 1992; 33: 661-4
38. Hebert MF, Roberts JP, Prueksaritanont T, et al. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52: 453-7
39. Gomez DY, Wacher VJ, Tomlanovich SJ, et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995; 58: 15-9
40. Ducharme MP, Provenzano R, Dehoorne-Smith M, et al. Trough concentration of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol 1993; 36: 457-9
41. Proppe DG, Hoch OD, McLean AJ, et al. Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function. Br J Clin Pharmacol 1995; 39: 337-8
42. Yee GC, Stanley DL, Pessa LJ, et al. Effect of grapefruit juice on blood cyclosporin concentration [see comments]. Lancet 1995; 345: 955-6
43. Johnston A, Holt DW. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995; 345: 122-3
44. Best NG, Trull AK, Tan KK, et al. Blood cyclosporin concentrations and the short-term risk of lung rejection following heart-lung transplantation. Br J Clin Pharmacol 1992; 34: 513-20
45. Kahan BD, Welsh M, Schoenberg L, et al. Variable oral absorption of cyclosporine: a biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996; 62: 599-606
46. Kahan BD. Neoral addresses two limitations of existing cyclosporin formulations: limited and variable drug absorption. In: Neoral: the new microemulsion formulation of cyclosporine. Cedar Knolls (NJ): World Medical Press, 1995; 12-8
47. Johnston A, Sketris I, Marsden JT, et al. A limited sampling strategy for the measurement of cyclosporine AUC. Transplant Proc 1990; 22: 1345-6
48. Ritschel WA, Adolph S, Ritschel GB, et al. Improvement of peroral absorption of cyclosporine A by microemulsions. Methods Find Exp Clin Pharmacol 1990; 12: 127-34
49. Kovarik JM, Mueller EA, Johnston A, et al. Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. Pharmacotherapy 1993; 13: 613-7
50. Pabst G, Jaeger H. Review of methods and criteria for the evaluation of bioequivalence studies. Eur J Clin Pharmacol 1990; 38: 5-10
51. Mueller EA. Recommendations of bioequivalence standards for the development of new oral formulations of cyclosporin A to avoid adverse clinical implications. Eur J Clin Res 1995; 7: 79-85
52. Mueller EA, Kovarik JM, van Bree JB, et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994; 11: 301-4
53. Mueller EA, Kovarik JM, van Bree JB, et al. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res 1994; 11: 151-5
54. Mueller EA, Kovarik JM, van Bree JB, et al. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients - a concentration-controlled comparison with the commercial formulation. Transplantation 1994; 57: 1178-82
55. Kovarik JM, Mueller EA, van Bree JB, et al. Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients. Ther Drug Monit 1994; 16: 232-7
56. Kovarik JM, Mueller EA, Vanbree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation - a multicenter investigation in kidney transplant patients. Transplantation 1994; 58: 658-63
57. Wahlberg J, Wilczek HE, Fauchald P, et al. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period. Transplantation 1995; 60: 648-52
58. Taesch S, Niese D. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients. Transpl Int 1994; 7: S263-6
59. Taesch S, Niese D, Mueller EA. Sandimmun Neoral, a new oral formulation of cyclosporin A with improved pharmacokinetic characteristics: safely and tolerability in renal transplant patients. Transplant Proc 1994; 26: 3147-9
60. Schmidt AG, Niese D, Krayenbuehl J, et al. 12-month follow-up of stable and de novo renal transplant patients on Sandimmun Neoral [abstract]. Acta Med Austriaca 1994; 21: 16
61. Offermann G, Korn A. Safety and tolerability of cyclosporin microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. Transplant Proc 1997. In press
62. Niese D. A double-blind randomized study of Sandimmun Neoral versus Sandimmun in new renal transplant recipients: results after 12 months. Transplant Proc 1995; 27: 1849-56
63. Pollard SG, Lodge PJ, UK Neoral Renal Study Group. Neoral vs Sandimmun: interim results of a randomised trial of efficacy and safety in preventing acute rejection in renal transplant recipients [abstract]. Proceedings of the XVI International Congress of the Transplantation Society; Barcelona. Transplant Proc 1997. In press
64. Barone G, Chang CT, Choc MG, et al. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. Transplantation 1996; 61: 875-80
65. Barone G, Bunke CM, Choc MG, et al. The safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomised, double-blind comparison in primary renal allograft recipients. Transplantation 1996; 61: 968-70
66. Kovarik JM, Mueller EA, Richard F, et al. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Transplantation 1996; 62: 759-63
67. Neumayer HH, Farber L, Haller P, et al. Clinical experience transferring kidney transplant patients from Sandimmun to Sandimmun Neoral - results after 3 months. Clin Nephrol 1995; 43 Suppl. 1: S27-32
68. Neumayer HH, Farber L, Haller P, et al. Clinical experience in transferring kidney transplant patients from Sandimmun to Sandimmun Neoral - results after 6 months. Transplant Proc 1995; 27: 2679-82
69. Kovarik JM, Kallay Z, Mueller EA, et al. Acute effect of cyclosporin on renal function following the initial changeover to a microemulsion formulation in stable kidney transplant patients. Transpl Int 1995; 8: 335-9
70. Svendsen UG. Transferring heart and lung patients to Neoral. In: Johnson R, editor. Rational use of Neoral. London: Royal Society of Medicine, 1996: 38-43
71. Dalrymple-Hay M, Meara M, Reynolds L, et al. Changing stable heart transplant recipients from Sandimmun to Neoral. Transplanl Proc 1996; 28: 2285-6
72. Pollard S. Transfer of liver transplant patients from Sandimmun to Neoral. In: Johnson R, editor. Rational use of Neoral. London: Royal Society of Medicine, 1996: 30-7
73. Sandoz Pharma (Basle). Data on file, study OLW116
74. Bokenkamp A, Offner G, Hover PF, et al. Improved absorption of cyclosporin A from a new microemulsion formulation: implications for dosage and monitoring. Pediatr Nephrol 1995; 9: 196-8
75. Hoppu K, Jalanko H, Laine J, et al. Comparison of conventional oral cyclosporine and cyclosporine microemulsion formulations in children with a liver transplant. Transplantation 1996; 62: 66-71
76. Tredger JM. Using cyclosporine Neoral immediately after liver transplantation. Ther Drug Monit 1995; 17: 638-41
77. Jamieson NV. De novo use of Neoral in liver transplant recipients. In: Neoral: the new microemulsion formulation of cyclosporine. Cedar Knolls (NJ): World Medical Press, 1995: 34-9
78. Freeman D, Grant D, Levy G, et al. Pharmacokinetics of a new oral formulation of cyclosporine in liver transplant recipients. Ther Drug Monit 1995; 17: 213-6
79. Mueller EA, Kallay Z, Kovarik JM, et al. Bile-independent absorption of cyclosporine from a microemulsion formulation in liver transplant patients. Transplantation 1995; 60: 515-7
80. Trull AK, Tan KKC, Tan L, et al. Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion. Br J Clin Pharmacol 1995; 39: 627-31
81. Rasmussen A, Hjortrup A, Hansen B, et al. Induction of immunosuppression by microemulsion cyclosporine in liver transplantation. Transplantation 1996; 62: 1031-3
82. Dunn SP, Cooney GF, Kulinsky A, et al. Absorption characteristics of a microemulsion formulation of cyclosporine in de novo pediatric liver transplant recipients. Transplantation 1995; 60: 1438-42
83. Pescovitz MD, Puente JG, Jindal RM, et al. Improved absorption of cyclosporine for microemulsion in a pediatric liver transplant recipient with cystic fibrosis. Transplantation 1996; 61: 331-3
84. Alberti D, Wallemacq P, Falchetti D, et al. Microemulsion formulation of cyclosporine in pediatric liver transplantation. Transplantation 1996; 61: 512-4
85. Gonzalez Ruiz M, deCos MA, Casafont F. Cholestasis-related cyclosporin malabsorption overcome by administration of Sandimmun Neoral(R): case report and review of the literature. Clin Drug Invest 1996; 11: 60-4
86. Ferrea G, Fioredda F, Loy A, et al. Oral microemulsion formulation substitutes for intravenous cyclosporin in child with graft-versus-host disease [letter]. Lancet 1994; 344: 480-1
87. Tan KK, Hue KL, Strickland SE, et al. Altered pharmacokinetics of cyclosporin in heart-lung transplant recipients with cystic fibrosis. Ther Drug Monit 1990; 12: 520-4
88. Williams SG, Westaby D, Tanner MS, et al. Liver and biliary problems in cystic fibrosis. Br Med Bull 1992; 48: 877-92
89. Tsang VT, Johnston A, Heritier F, et al. Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis: effects of pancreatic enzymes and ranitidine. Eur J Clin Pharmacol 1994; 46: 261-5
90. Tan KKC, Trull AK, Uttridge JA, et al. Relative bioavailability of cyclosporin from conventional and microemulsion formulations in heart-lung transplant candidates with cystic fibrosis. Eur J Clin Pharmacol 1995; 48: 285-9
91. Girault D, Haloun A, Viard L, et al. Sandimmun Neoral improves the bioavailability of cyclosporin A and decreases inter-individual variations in patients affected with cystic fibrosis. Transplant Proc 1995; 27: 2488-90
92. Mikhail GW, Eadon H, Rogers P, et al. Microemulsion formulation increases cyclosporin bioavailability in cystic fibrosis. Lancet 1995; 346: 1638-9
93. Jacqz-Aigrain E, Montes C, Brun P, et al. Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children. Eur J Clin Pharmacol 1994; 47: 61-5
94. Feutren G. The optimal use of cyclosporin A in autoimmune diseases [published erratum appears in J Autoimmun 1992 Aug; 5 (4): 545]. J Autoimmun 1992; 5 Suppl. A: 183-95
95. Holt DW, Johnston A. Cyclosporin monitoring: its role in autoimmune indications [review]. J Autoimmun 1992; 5 Suppl. A: 177-82
96. van den Borne BE, Landewe RB, Goei The HS, et al. Relative bioavailability of a new oral form of cyclosporin A in patients with rheumatoid arthritis. Br J Clin Pharmacol 1995; 39: 172-5
97. Elder CA, Moore M, Chang CT, et al. Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. J Clin Pharmacol 1995; 35: 865-75
98. Gulliver WP, Murphy GF, Hannaford VA, et al. Increased bioavailability and improved efficacy, in severe psoriasis, of a new microemulsion formulation of cyclosporin. Br J Dermatol 1996; 135 Suppl. 48: 35-9
99. Bourke JF, Berth-Jones J, Holder J, et al. A new microemulsion formulation of cyclosporin (Neoral) is effective in the treatment of cyclosporin-resistant dermatoses. Br J Dermatol 1996; 134: 777-9
100. Kovarik JM, Vernillet L, Mueller EA, et al. Cyclosporine disposition and metabolite profiles in renal transplant patients receiving a microemulsion formulation. Ther Drug Monit 1994; 16: 519-25
101. Holt DW, Johnston A. Cyclosporin and vitamin E. Lancet 1991; 338: 697
102. Moore R. Cost issues in the use of Neoral. In: Johnson R, editor. Rational use of Neoral. London: Royal Society of Medicine, 1996: 44-9
103. Keown PA. Pharmacokinetic, economic, and pharmacoepidemiological analyses of Neoral in renal transplantation in Canada. In: Neoral: the new microemulsion formulation of cyclosporine. Cedar Knolls (NJ): World Medical Press, 1995: 40-6
104. Holt DW, Johnston A. Bioequivalence of two oral cyclosporine preparations - commentary. Arzneimittelforschung 1995; 45-2: 1242-3
105. Johnston A, Keown PA, Holt DW. Simple bioequivalence criteria - are they relevant to critical dose drugs? Experience gained from cyclosporin. Ther Drug Monitor 1997. In press
106. Holt DW. Long-term efficacy and safety study (LOTESS). In: Johnson RWG, editor. Transplantation '95. The outlook for transplantation towards 2000. London: Royal Society of Medicine, 1995; 73-6